Skip to main
DYN

Dyne Therapeutics (DYN) Stock Forecast & Price Target

Dyne Therapeutics (DYN) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Dyne Therapeutics is an innovative clinical-stage company with a strong pipeline of targeted therapies for neuromuscular diseases. The company's unique FORCE platform addresses the limitations of traditional drug delivery methods and has shown promising results in clinical trials. With strong IP protection and an expanding portfolio, Dyne has the potential to be a key player in the neuromuscular disease market.

Bears say

Dyne Therapeutics is facing numerous challenges and risks that could hinder its progress and success in the highly competitive biotechnology and pharmaceutical industries. These include a lack of current revenue-generating products, the need to raise additional capital, and the potential for regulatory uncertainties and challenges. Furthermore, the company's pipeline is focused on rare diseases, which may limit its potential market and revenue opportunities. All of these factors contribute to a negative outlook for Dyne Therapeutics's stock in the near future.

Dyne Therapeutics (DYN) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dyne Therapeutics (DYN) Forecast

Analysts have given Dyne Therapeutics (DYN) a Buy based on their latest research and market trends.

According to 10 analysts, Dyne Therapeutics (DYN) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dyne Therapeutics (DYN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.